Navigation Links
Sorrento Therapeutics and IGDRASOL to Present Late Stage Clinical Data Updates on their Oncology Nanomedicine Platform at the Joint Meeting of the European Foundation for Clinical Nanomedicine and European Technology Platform on Nanomedicine in Base
Date:6/21/2013

SAN DIEGO and IRVINE, Calif., June 21, 2013 /PRNewswire/ -- Sorrento Therapeutics, Inc. (OTCQB: SRNE; Sorrento) and IGDRASOL announced today that the companies will present updates of their analyses of proprietary late clinical stage paclitaxel formulations, IG-001 (Cynviloq™) and IG-004 (TOCOSOL® paclitaxel) at the joint meeting of the European Foundation for Clinical Nanomedicine (CLINAM) and the European Technology Platform on Nanomedicine (ETPN) in Basel, Switzerland on June 23 - 26. Sorrento has the right to acquire IGDRASOL pursuant to a previously-announced option agreement, entered into in March 2013.

IGDRASOL'S data mining of the clinical data for both IG-001 and IG-004 has generated exciting insights into the field of nanomedicine, which will be presented at the joint meeting. These findings are highly relevant to the theme of this year's conference, namely "Nanomedicine & Targeted Medicine – the paradigm of precise, highly effective and innocuous medicine for the benefit of patients and mankind".

IG-001 (Cynviloq™) is a next-generation, branded, micellar diblock copolymeric paclitaxel formulation currently approved and marketed in several countries as Genexol-PM®. It has completed Phase 1 or 2 trials in metastatic breast cancer (MBC), non-small cell lung cancer (NSCLC), pancreatic cancer, ovarian cancer and bladder cancer in the U.S. and/or ex-U.S. IGDRASOL is preparing for an "End of Phase 2" meeting scheduled with the U.S. Food & Drug Administration (FDA) in July 2013, regarding the clinical development of Cynviloq™. As an injectable nanoparticle formulation of paclitaxel, Cynviloq™ may be eligible for approval through the FDA's 505(b)(2) bioequivalence regulatory pathway versus albumin-bound paclitaxel (nab-paclitaxel; Abraxane®) in its currently approved MBC and NSCLC ind
'/>"/>

SOURCE Sorrento Therapeutics, Inc.
Copyright©2012 PR Newswire.
All rights reserved

Page: 1 2 3 4 5

Related medicine technology :

1. Sorrento Therapeutics Receives Frost & Sullivans Prestigious 2013 Global Investment Opportunity Award in the Oncology Market
2. Sorrento Therapeutics Receives Frost & Sullivans 2013 Global Investment Opportunity Award in Oncology
3. Sorrento Therapeutics to Present at the Jefferies 2013 Global Healthcare Conference in New York City
4. Sorrento Therapeutics, Inc. announces its approach to developing human antibody therapeutics against MRSA receives continued support from the National Institute of Allergy and Infectious Diseases
5. Sorrento Therapeutics, Inc. and IGDRASOL Announce Presentation on Non-Biologic Nanoparticle paclitaxel (NBN-Pac) Formulations for the Treatment of Solid Tumors at the Nanomedicine 2013 Meeting in Barcelona, Spain
6. Sorrento Therapeutics Signs Exclusive Option to Acquire IGDRASOL
7. Sorrento Therapeutics Awarded Third Phase I STTR Grant
8. Orexigen Therapeutics Announces Upcoming Clinical Data Presentations at American Diabetes Association Annual Scientific Meeting
9. Echo Therapeutics Announces Closing of Public Offering of Common Stock And Full Exercise of Over-Allotment Option by the Underwriter
10. Nektar Therapeutics Presents Positive Data from Human Abuse Liability Study for NKTR-181, a First-in-Class Investigational Opioid to Treat Chronic Pain, at 2013 Annual Meeting of The College on Problems of Drug Dependence
11. Life Technologies Signs Licensing Agreement with Suzhou Ribo Life Sciences for Development of siRNA Therapeutics in China
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:3/27/2015)... , March 27, 2015 Zimmer Holdings, Inc. (NYSE ... fixation system for trauma patients. Available in ... ® External Fixation System from Zimmer is a ... materials.   The XtraFix System allows surgeons ... the external fixation process, resulting in saved time, costs and ...
(Date:3/27/2015)... , March 27, 2015 ... International Exhibition of Senior Care, Rehabilitation Medicine and Healthcare, ... senior service industry, will be held at Shanghai New ... On 25 February, 2015,  Implementation Suggestions on Encouraging Private ... Industry, which was jointly issued by the Ministry of ...
(Date:3/27/2015)... March 27, 2015  Valeant Pharmaceuticals International, Inc. (NYSE: ... of its previously announced registered offering of common shares ... "Offering"). Pursuant to the Offering, the Company issued 7,286,432 ... for aggregate gross proceeds of approximately $1.45 billion. On ... Securities and Exchange Commission a final prospectus supplement to ...
Breaking Medicine Technology:Zimmer Debuts New Modular External Fixation System 2Zimmer Debuts New Modular External Fixation System 3CHINA AID, the 10th China International Exhibition of Senior Care, Rehabilitation Medicine and Healthcare to be held in April 2CHINA AID, the 10th China International Exhibition of Senior Care, Rehabilitation Medicine and Healthcare to be held in April 3CHINA AID, the 10th China International Exhibition of Senior Care, Rehabilitation Medicine and Healthcare to be held in April 4CHINA AID, the 10th China International Exhibition of Senior Care, Rehabilitation Medicine and Healthcare to be held in April 5CHINA AID, the 10th China International Exhibition of Senior Care, Rehabilitation Medicine and Healthcare to be held in April 6Valeant Pharmaceuticals Closes Offering Of $1.45 Billion Of Common Shares 2Valeant Pharmaceuticals Closes Offering Of $1.45 Billion Of Common Shares 3
... Jan. 12, 2011 CredenceHealth announced today ... for Meaningful Use in Clinical Quality Measures (i.e. eMeasures). ... receive this stand-alone certification. " CCHIT ... so that companies are now able to offer these ...
... INDIANAPOLIS, Jan. 12, 2011 Eli Lilly and Company ... and Drug Administration (FDA) Gastrointestinal Drugs Advisory Committee voted ... enzyme replacement therapy (PERT), currently under FDA review for ... During the meeting, the committee had questions about ...
Cached Medicine Technology:CredenceHealth's CHlive Meaningful Use Certified (ONC-ATCB 2011/2012 Certification) 2CredenceHealth's CHlive Meaningful Use Certified (ONC-ATCB 2011/2012 Certification) 3Statement From Lilly on FDA Advisory Committee Recommendation Regarding Liprotamase New Drug Application for Treatment of Exocrine Pancreatic Insufficiency 2
(Date:3/28/2015)... Aureus Medical Group (web: aureusmedical.com), ... therapy jobs, has announced that it will participate ... Association Annual Conference to be held April 10-11, ... Columbus, OH. , The OPTA Annual Conference ... products and services. , Representatives from Aureus ...
(Date:3/28/2015)... ARDX will sponsor the 7th Annual Women’s ... the Chesapeake Conference Center in Chesapeake, Virginia. Each year, ... for women in the Hampton Roads region. The 2015 ... Lives. Women grow stronger through sharing their stories and ... year the WWC™ theme is T-talk where we will share ...
(Date:3/27/2015)... March 27, 2015 The Monogamy ... dating experts Samantha Sanderson and Jason Rogers has just ... of media attention. The commotion surrounding the course's launch ... him to publish an in-depth review of the new ... the men in their lives suddenly start pulling away ...
(Date:3/27/2015)... The federal court overseeing thousands of ... medication increases the risk that a patient will develop ... Dismiss four individual cases that had been filed in ... in the U.S. District Court, District of South Carolina, ... were warranted because the plaintiffs in those claims had ...
(Date:3/27/2015)... CA (PRWEB) March 27, 2015 Healthpointe ... Stanley G. Katz, M.D., is now treating knee and ... including Anaheim , Long Beach, and La Mirada. ... of acute knee and hip joint disorders as well ... Katz is passionate in returning his patients back to ...
Breaking Medicine News(10 mins):Health News:Healthcare Staffing Leader, Aureus Medical Group, to Exhibit at the Ohio Physical Therapy Association Annual Conference 2Health News:The Monogamy Method - Review Of Samantha Sanderson & Jason Rogers' Relationship Program Released 2Health News:Lipitor Lawsuits Move Forward in Federal Multidistrict Litigation, as Court Rules on Pfizer’s Motion to Dismiss Certain Cases 2Health News:Lipitor Lawsuits Move Forward in Federal Multidistrict Litigation, as Court Rules on Pfizer’s Motion to Dismiss Certain Cases 3Health News:Fellowship-Trained and Board-Certified Orthopedic Surgeon is Now Treating Knee and Hip Joint Disorders in Anaheim, California 2Health News:Fellowship-Trained and Board-Certified Orthopedic Surgeon is Now Treating Knee and Hip Joint Disorders in Anaheim, California 3
... Sept. 23 PharmAthene, Inc. (NYSE Amex: PIP ... chemical threats, announced today that management will present at the ... to present on Tuesday, September 29(th) 2009 at 11:00 a.m. ... New York City. , PharmAthene,s presentation will be webcast ...
... PAUL, Minn., Sept. 23 Prime Therapeutics (Prime), a nationwide pharmacy ... the organization as senior vice president of human resources. , ... all areas of human resources, facilities, safety and security management. ... to our executive team," said Kim Mageau, interim president and CEO ...
... , RENO, NV, Sept. 23 /PRNewswire-FirstCall/ - (Pinksheets: CMHS) ... its Articles of Incorporation to change the Company,s name ... part of the Company,s previously announced plans to change ... of profitable clean energy fields (such as natural gas) ...
... , , , ... Program , , - SDA, CDC Initiative Encourages Hygiene ... York Students Also Recognized , , WASHINGTON, Sept. 23 ... One group of students hit the science lab. A language arts class used the ...
... MO, 23 September 2009 Elsevier, a leading ... and services announced today, that the Editors of ... the foremost publication of information about evidence-based dental ... to its recognized experts and valued peer reviewers. ...
... are part of an international team that has discovered ... with hepatitis C who are most likely to benefit ... Max Moldovan from the institute,s Bioinformatics division worked with ... analyse the genomes of more than 800 people, including ...
Cached Medicine News:Health News:Prime Therapeutics Hires Jacqueline Chase as Senior Vice President of Human Resources 2Health News:CMHS (dba Hybrid Energy Holdings) changes name of corporation and prepares to file for ticker symbol change with FINRA 2Health News:'Bubble Trouble' Team Hits the Lab for Good Hygiene 2Health News:'Bubble Trouble' Team Hits the Lab for Good Hygiene 3Health News:'Bubble Trouble' Team Hits the Lab for Good Hygiene 4Health News:Journal of Evidence-Based Dental Practice to offer continuing education units for reviewers 2Health News:Discovery could improve hepatitis C treatment 2
... STA R is a fully ... for clotting, chromogenic and immunological, latex ... analyser using standard 5-position racks as ... 200 different methods, up to 70 ...
... Surgicutt family of bleeding time devices provides ... adults, Surgicutt Jr. for children and Surgicutt ... family is engineered to perfect the bleeding ... the variables that have previously hindered test ...
... tenderfoot infant heelstick device uses a highly sharpened ... a gentle arc. The incision produced is carefully ... where most nerve fibers are located, but through ... high quality blood sample with significantly less pain ...
The Unistik 3 family of single use safety lancets has 4 models for use across all clinical environments....
Medicine Products: